Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite , President and CEO, and Vikram Jog, Chief
View HTML
Toggle Summary CyTOF and Maxpar Direct Technologies Utilized in Study Characterizing Immune and Inflammatory Responses in Pregnant Women Infected with SARS-CoV-2
Findings in Nature Communications Provide Insights That May Help Guide Patient Care Research Study Conducted in Collaboration with Fluidigm’s Therapeutic Insights Services SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
View HTML
Toggle Summary Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit
SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor
View HTML
Toggle Summary Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million
Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million . SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools
View HTML
Toggle Summary Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry
Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine
Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif. , July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2021 financial results on Thursday,
View HTML
Toggle Summary Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of Ownership
A New Platform to Simplify Deep Profiling of the Human Immune System SOUTH SAN FRANCISCO, Calif. , May 25, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the
View HTML
Toggle Summary Imaging Mass Cytometry Utilized by Global Consortium Focused on New Precision Medicine Approaches for Treatment of Rheumatoid Arthritis
FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in Rheumatoid Arthritis Therapy SOUTH SAN FRANCISCO, Calif. , May 24, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in several upcoming
View HTML